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2357primary care physician; 2) systematic screening of fam-
ilies with known genetic diseases after diagnosis in a
relative; 3) incidental and fortuitous ﬁndings on clinical
examination or imaging, detected during evaluation for
another medical problem; 4) systematic screening of large
populations, such as high school and college-aged ath-
letes, for the purpose of determining eligibility for
competitive sports, with or without diagnostic testing;
and 5) symptoms associated or unassociated with sports.
It is likely that a large number (or even most) athletes
with cardiovascular disease come to clinical attention
based on the circumstances described in items 1 through 3,
rather than with formal preparticipation screening.
GENERAL CONSIDERATIONS
Currently, broad-based cardiovascular screening is prac-
ticed systematically in athletes at all levels of performance
(not conﬁned to the elite) in only 3 countries: in the United
States, with personal/family history and physical exami-
nation (but without ECGs) (1–3,19,20), and in both Italy
(4–6,9) and Israel (7), with 12-lead ECGs in addition to his-
tory and physical examination. In many European coun-
tries, screening of athletes is largely limited to those
performing at the elite level (e.g., in international,
Olympic, or professional sports) (21). The potential beneﬁt
of such initiatives is the identiﬁcation of a small number of
people with potentially lethal genetic or congenital car-
diovascular diseases (e.g., hypertrophic cardiomyopathy)
so that 1) they may be withdrawn from competitive sports
to decrease their personal risk and generally make the
athletic ﬁeld a safer environment, and 2) in the process,
some high-risk people may be recognized who may be
candidates for disease-modifying medical or surgical
intervention, or for prevention of sudden death with
implantable deﬁbrillators. In 1973, the Japanese School
Health Law mandated cardiovascular screening with
modiﬁed ECG and history/physical examination for thou-
sands of children in the ﬁrst, seventh, and tenth grades
(22,23). Few disease-related data have emerged from this
initiative, although a variety of generally minor cardio-
vascular abnormalities or arrhythmias (unassociated with
underlying organic heart disease) were identiﬁed in only
2% to 3% of children (23).
DEBATE AND CONTROVERSY
Within the context of these potential beneﬁts, there has
nevertheless been substantial discussion surrounding the
most appropriate and efﬁcacious strategy for screening,
including national federally sponsored and mandated car-
diovascular screening. For example, Italian investigators
have intensely promoted screening with a routine 12-lead
ECG (as well as history and physical examination) based
on a unique>30-year programmandated by Italian law andsupported by sports medicine physicians dedicated full-
time to the program (4–6,9). Since 1997, Israel has main-
tained a similar mandatory ECG-based initiative and
national sports law (7). For >50 years, it has been
customary practice in the United States to routinely screen
high school and college-aged athletes with history and
physical examination (but without noninvasive testing)
(1–3,19,20). In contrast, Denmark has pointedly rejected
systematic screening for cardiovascular disease in both
athletes and any other segment of the population as being
unjustiﬁed given the low event rate (12,13). Other than
Japan (22,23), no country has systematically attempted
broad-based cardiovascular screening in general healthy
populations (not limited to athletes), with or without ECGs.
UNIVERSAL SCREENING: ECGs VERSUS
HISTORY AND PHYSICAL EXAMINATION
Preparticipation screening for cardiovascular disease with
personal/family history and physical examination has
been the customary practice for all high school and
college-aged competitive athletes in the United States for
decades, independent of their performance level. This
process is guided by the 14-point history and physical
examination elements proposed by the American Heart
Association (AHA) (1). The AHA recommendations
acknowledge that athletes and others with underlying
(but undiagnosed) cardiovascular abnormalities may well
manifest clinical warning signs (e.g., chest pain, excessive
exertional dyspnea, or syncope) identiﬁable by careful
and systematic history. Because most diseases respon-
sible for sudden death in the young are genetic/familial, a
thorough family history may raise suspicion of the dis-
order. An organic heart murmur can alert the examining
physician to valvular or other abnormalities, including
left ventricular outﬂow tract obstruction.
A controversy persists as to whether an ECG (in
addition to history and physical examination) is a supe-
rior strategy to history/physical examination alone for
detecting potentially lethal cardiovascular disease,
particularly when taking into account the important
issues of false-negative and false-positive results, as well
as cost and resource availability (1). Indeed, studies
comparing these 2 strategies have failed to demonstrate a
mortality beneﬁt for ECG screening (18).
The debate between those who strongly promote
routine ECGs and those opposed to ECGs as a routine
screening tool is not fully resolved as yet, although a
substantial literature consisting largely of editorials and
viewpoint commentaries is accumulating rapidly. Never-
theless, several points are indisputable. First, the 12-lead
ECG, although a mainstay of hospital-based cardiovascu-
lar practice for decades, is an unproven diagnostic tool for
reliable detection of cardiovascular disease in generally
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screening and mortality have been driven primarily by
only 1 database, from the Veneto region of Italy (9% of the
national population) as part of its long-term screening
program (6,9). This ambitious Italian initiative has been
shown to be successful in identifying some at-risk ath-
letes with potentially lethal cardiovascular disease (pri-
marily right ventricular cardiomyopathy, which appears
to be endemic in this area of Italy), resulting in their
mandatory withdrawal from sports. In addition, a sharp
decrease in mortality rate over a 30-year period was
demonstrated, which these investigators attributed to
incorporation of the 12-lead ECG into the screening pro-
gram in the early 1980s.
Third, the Italian data showing that ECG screening re-
duces mortality in athletes have yet to be replicated
elsewhere, and evidence from the United States (18) and
Israel (7) appears to dispute or diminish the value of the
ECG in reducing athlete mortality. For example, contem-
porary mortality rates in US athletes from Minnesota,
where screening is limited to history and physical exam-
ination, do not differ from those in the Veneto region of
Italy, where the ECG is used routinely (18); furthermore,
athlete mortality rates in Israel were not different before
and after legislation for mandatory ECGs (7). The fact that
it has been difﬁcult to consistently show a reduction in
athlete mortality directly attributable to routine ECGs is
an observation that may be driven by the generally low
event rates in competitive athletes with cardiovascular
disease (1–3,6,10,11,18,24–26).
RELEVANCE OF SUDDEN DEATH INCIDENCE
TO SCREENING
Indeed, the low frequencywithwhich sudden deaths occur
in the competitive athlete population negatively impacts
the justiﬁcation for broad-based screening in large pop-
ulations of young people, as well as the weight that can be
afforded to this issue as a public health problem. In this
regard, there is now overwhelming evidence that these
events are relatively uncommon, albeit exceedingly tragic
in each case. Most data place these cardiovascular sudden
deaths in the range of approximately 1 in 80,000 to 1 in
200 000 participants per year, much less common in rela-
tive terms than motor vehicle accidents (by 5,000-fold),
suicide, drugs, homicide, or cancer in the same age group
and similar in frequency to that of fatal lightning strikes
(1,11,25). In a college (National Collegiate Athletic Associ-
ation) athlete population, drugs and suicide combined
accounted for a similar number of deaths as conﬁrmed
cardiac disease (24), although a non–forensic-based
analysis reported a higher incidence for sudden death (27).
Notably, the absolute number of sudden deaths
attributable to documented cardiovascular disease incompetitive athletes is small in populations for which
forensic data are reported. For example, the 33-year US
Sudden Death in Athletes Registry has reported a
maximum of 75 such deaths in any given year nationally
(10), and the Veneto database reports 55 sudden deaths in
26 years, or onlyz2 per year (6). In other populations, the
average number of conﬁrmed cardiovascular deaths
annually is much less, for instance, <1 in Minnesota high
school athletes (11) or z4 in college (National Collegiate
Athletic Association) athletes (24). Notably, false-negative
screening results are a major concern, in which the system
fails to identify the cardiac diseases for which it is in fact
established. Indeed, a substantial proportion of athletes
(z30% to 40%) may die suddenly of cardiovascular ab-
normalities that would not necessarily be reliably detec-
ted by screening even with ECGs (1,11,24,25).
UNIVERSAL ECG SCREENING
On 3 occasions (1996, 2007, and 2014), AHA consensus
expert panels evaluated and decided not to support
mandatory national athlete screening in the United States,
particularly with routine use of ECGs (1–3). Indeed, sudden
cardiovascular deaths in athletes are rare (albeit tragic)
events, insufﬁcient in number to be judged as a major
public health problem or to justify a change in national
healthcare policy. The most frequently cited obstacles to
mandatory national screening of trained athletes are as
follows: 1) the large number of athletes to be screened
nationally on an annual basis (i.e., z10 to 12 million); 2)
the low incidence of events (1,8,10,11,18,24–26); 3) the
substantial number of expected false-negative and false-
positive results, in the range of 5% to 20% depending on
the speciﬁc ECG criteria used (1–3,28–32); 4) cost-efﬁcacy
considerations, that is, the extensive resources and ex-
penses required versus few events in absolute numbers;
5) liability issues that unavoidably impact physicians with
the sole responsibility to disqualify athletes from compe-
tition and enforce that decision; 6) the lack of resources or
physicians dedicated to performing examinations and
interpreting ECGs, in contrast to the long-standing
sports medicine program in Italy (4–6,9); 7) the inﬂu-
ence of observer variability, technical considerations, and
the impact of ethnicity/race on the interpretation of
ECGs, which is particularly important for multicultural
athlete populations such as in the United States; 8)
the need for repetitive (i.e., annual) ECG screening during
adolescence, given the possibility of developing pheno-
typic evidence of cardiomyopathies during this time
period or later (33); 9) the logistical challenges and costs
related to second-tier conﬁrmatory screening with imag-
ing and other testing, should primary evaluations raise
the suspicion of cardiac disease; and 10) recognition
that even with testing, screening cannot be expected to
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normalities, and a signiﬁcant false-negative rate may
occur (34).
NONUNIVERSAL SCREENING FOR ATHLETES
Screening programs on a smaller, nonnational basis have
been implemented in somehigh schools, colleges, and local
communities that use ECGs (or echocardiograms) with
varying expertise, quality control, and results for identi-
fying important cardiac disease. Consistently, the AHA has
not opposed ECG-based screening initiatives (often per-
formed by volunteers) in smaller venues; however, for such
screening initiatives, the AHA has prudently advised
adequate quality control with due consideration for the
prominent limitations of the process (including false-
negative and false-positive test results), so that the risks
and beneﬁts can be understood and are acceptable to all
participants, communities, and organizations (1–3).
There are certain known and anticipated limitations in
the use of ECGs in population screening, including but not
limited to false-positive and false-negative test results,
technical and interpretation issues, “gray zone” ambig-
uous diagnoses, and cost and logistics involved in arran-
ging second-tier diagnostic testing, all of which promote
anxiety, uncertainty, and legal considerations (1,12,25,34).
SCREENING AND RACE
Sudden deaths attributable to cardiovascular disease have
been reported in athletes of both sexes and a variety of
races, although they are much less common in females (by
1:9) (10,14). Preparticipation screening is warranted with
the same frequency and criteria, independent of sex and
across racial lines. In particular, although hypertrophic
cardiomyopathy unrecognized during life is a frequent
cause of sudden death in African-Americans on the athletic
ﬁeld and a major impetus for screening in the black com-
munity (1,14,35), there is no evidence to justify different or
separate screening strategies based on race. However, it is
becoming increasingly apparent that ethnic/racial differ-
ences in ECG patterns may signiﬁcantly impact the deﬁni-
tion of normality (30,36–39) and therefore potentially the
outcome of the screening process for minorities.
ETHICAL CONSIDERATIONS:
WHO SHOULD BE SCREENED?
Unfortunately, often overlooked in the ECG screening
debate is the potentially troublesome ethical dilemma
created by conﬁning (or proposing to limit) screening for
potentially lethal diseases to those who choose engage-
ment in competitive sports, while in the process
excluding those who are not athletes. The degree to which
people engaged in competitive athletics are at greater risk(given unsuspected underlying heart disease) is not
completely resolved. It is likely that the absolute number
of sudden deaths is highest in nonathletes because that
segment of the population is much larger in size. The AHA
maintains the position (1) that theoretically there is no
compelling reason to conﬁne screening for cardiovascular
disease to young competitive athletes, and exclude
non-athletes.
Recommendations
The guidelines presented here are those of the AHA/
American College of Cardiology 2014 initiative (1).
1. It is recommended that the AHA’s 14-point screening
guidelines and those of other societies, such as the
American Academy of Pediatrics’ Preparticipation
Physical Evaluation, be used by examiners as part
of a comprehensive history taking and physical ex-
amination to detect or raise suspicion of genetic/
congenital cardiovascular abnormalities (Class I;
Level of Evidence C).
2. It is recommended that standardization of the ques-
tionnaire forms used as guides for examiners of high
school and college athletes in the United States be
pursued (Class I; Level of Evidence C).
3. Screening with 12-lead ECGs (or echocardiograms) in
association with comprehensive history-taking and
physical examination to identify or raise suspicion of
genetic/congenital and other cardiovascular abnor-
malities may be considered in relatively small cohorts
of young healthy people 12 to 25 years of age, not
necessarily limited to competitive athletes (e.g., in
high schools, colleges/universities or local commu-
nities). Close physician involvement and sufﬁcient
quality control is mandatory. If undertaken, such
initiatives should recognize the known and antici-
pated limitations of the 12-lead ECG as a population
screening test, including the expected frequency of
false-positive and false-negative test results, as well
as the cost required to support these initiatives over
time (Class IIb; Level of Evidence C).
4. Mandatory and universal mass screening with 12-lead
ECGs in large general populations of young healthy
people 12 to 25 years of age (including on a national
basis in the United States) to identify genetic/
congenital and other cardiovascular abnormalities is
not recommended for athletes and nonathletes alike
(Class III, no evidence of beneﬁt; Level of Evidence C).
5. Consideration for large-scale, general population,
and universal cardiovascular screening in the age
group 12 to 25 years with history taking and physical
examination alone is not recommended (including
on a national basis in the United States) (Class III,
no evidence of beneﬁt; Level of Evidence C).
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